How Safe Are Biosimilars? - Implications of FDA and EMA Guidances and European Experience since 2006 - Part 2
Written By : Dr. Hoss A Dowlat
VP, Global Strategy, Regulatory Affairs
PharmaBio Consulting, Freiburg, Germany
Published on July 2012
DownloadHow Safe Are Biosimilars? - Implications of FDA and EMA Guidances and European Experience since 2006 - Part 1
Written By : Dr. Hoss A Dowlat
VP, Global Strategy, Regulatory Affairs
PharmaBio Consulting, Freiburg, Germany
Published on May 2012
DownloadBiosimilars Breaching Borders: How FDA and EMA Find Common Ground
Written By : Dr. Hoss A Dowlat
VP, Global Strategy, Regulatory Affairs
PharmaBio Consulting, Freiburg, Germany
Published on May 2012
DownloadEuropean and Canadian Experience Providing Insights into DEVELOPING BIOSIMILAR OR SUBSEQUENT ENTRY BIOLOGICS
Written By : Dr. Hoss A Dowlat
VP, Global Strategy, Regulatory Affairs
PharmaBio Consulting, Freiburg, Germany
Published on April 2012
DownloadThe importance & impact of the EU RMP& US REMS to risk-benefit assessments
Written By : Dr. Hoss A Dowlat
VP, Global Strategy, Regulatory Affairs
PharmaBio Consulting, Freiburg, Germany
Published on April 2012
DownloadThe current status of biosimilar biologics : Part 1: An international perspective
Written By : Dr. Hoss A Dowlat
VP, Global Strategy, Regulatory Affairs
PharmaBio Consulting, Freiburg, Germany
Published on April 2012
DownloadThe current status of biosimilar biologics Part 2 : Practical considerations in international development through European lessons learned
Written By : Dr. Hoss A Dowlat
VP, Global Strategy, Regulatory Affairs
PharmaBio Consulting, Freiburg, Germany
Published on April 2012
DownloadPerception And Realities of Clinical Safety of BioSimilars : EU & US Perspectives: Part 1
Written By : Dr. Hoss A Dowlat
VP, Global Strategy, Regulatory Affairs
PharmaBio Consulting, Freiburg, Germany
Published on April 2012
DownloadPerception And Realities of Clinical Safety of BioSimilars : EU & US Perspectives: Part 2
Written By : Dr. Hoss A Dowlat
VP, Global Strategy, Regulatory Affairs
PharmaBio Consulting, Freiburg, Germany
Published on April 2012
DownloadContent Disclaimer
Contents in our website are from external websites. Links to and content from external website are provided for the convenience of users. Biopractice.com takes no responsibility for the content of such links and websites.